News | Patient Positioning Radiation Therapy | September 22, 2017

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017

Series of poster presentations, late-breakers and panel discussions will examine clinical and quality of life benefits of novel absorbable hydrogel spacing technology for prostate cancer treatment

Augmenix to Release New SpaceOAR Hydrogel Clinical Data at ASTRO 2017

September 22, 2017 — Augmenix Inc. announced a preview of clinical data that will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2017), Sept. 24-27 in San Diego. The presentations will provide new insights on the clinical and quality of life benefits of the company’s novel absorbable hydrogel spacing technology in providing protection during radiation therapy.

SpaceOAR hydrogel, Augmenix’s lead product, is U.S. Food and Drug Administration (FDA)-cleared and is designed to protect the rectum in men undergoing radiation therapy for prostate cancer.

Most notably at ASTRO 2017, results from the first prospective study evaluating the efficacy of SpaceOAR hydrogel in patients undergoing high-dose stereotactic body radiation therapy (SBRT) for prostate cancer will be presented as a late-breaking clinical trial on Tuesday, Sept. 26. Additionally, the first five-year quality of life data results in prostate cancer patients treated with SpaceOAR hydrogel will unveiled the same day in an oral presentation, demonstrating significant bowel and sexual function benefits. A didactic industry-sponsored panel discussion on the present and future role of hydrogel spacing in the treatment of prostate cancer, led by renowned radiation oncologists from around the world, will occur on Monday, Sept. 25.

Following is a detailed schedule of the company’s events in chronological order (times are U.S. Pacific Daylight Time):

Sunday, September 24

The following poster presentations will take place from 1:15 p.m. – 2:45 p.m. in the Poster Hall:

  • Poster Presentation (No : 2559): Dosimetry for Organs at Risk With and Without Use of Perirectal Hydrogel Spacer in Prostate Cancer Patients Treated With SBRT
    • Presented by: Daniel B. Fried, M.D., Ph.D., MPH
  • Poster Presentation (No : 2572): A Pilot Study – The Role of Radio-Opaque Hydrogel Tissue Marker in the Treatment of Postprostatectomy Intensity Modulated Radiation Therapy
    • Presented by Huong Ho, DO
  • Poster Presentation (No : 3383): Updated Retrospective Dose Volume Histogram Analysis of High Dose Rate Prostate Brachytherapy Patients With Hydrogel Spacer Implantation
    • Presented by Sean Cavanaugh, M.D.

 

Monday, September 25

  • Industry-Expert Theatre: Present and Future Role of Hydrogel Spacing in the Treatment of Prostate Cancer – 3 & 5 Year QOL Evidence and Stereotactic Body Radiation Therapy (SBRT) Experience
    • Time/Location: 12:30 p.m. – 1:30 p.m. Exhibit Hall – Theatre 1
    • Speakers: Robert Timmerman, M.D., professor of radiation oncology and neurology at the University of Texas Southwestern Medical Center in Dallas; Michael Zelefsky, M.D., professor of radiation oncology, vice-chair of the Department of Radiology and chief of the Brachytherapy Service at Memorial Sloan-Kettering Cancer Center in New York City; Daniel Hamstra, M.D., Ph.D., clinical director and professor at William Beaumont Oakland University Medical School, Department of Radiation Oncology, Beaumont Health, Dearborn, Mich.; and Prof. Dr. Michael Pinkawa, director of the Department of Radiation Oncology, MediClin Robert Janker Klinik in Bonn, Germany.
    • Moderator: Rodney Ellis, M.D., vice chair for clinical affairs at the University Hospitals Cleveland Medical Center and associate professor, radiation oncology at Case Western Reserve University in Cleveland.
  • Poster Presentation (No : 3613): The Rectal Dosimetric Effects of Perirectal Hydrogel Spacers in Men Undergoing Prostate Stereotactic Body Radiation Therapy (SBRT)
    • Time/Location: 4:15 p.m. – 5:45 p.m. Poster Hall
    • Presenter: Shaan Kataria, M.D.

Tuesday, September 26

  • Late-Breaking Abstracts Special Session (SS 22): Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer
    • Time/Location: 7:45 a.m. – 9 a.m. Room 5A
    • Presenter: Michael Folkert, M.D.
  • ePoster Presentation (No: 1083): Quality of Life after Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: Five Year Results
    • Time/Location: 1:12 p.m. Room 5B
    • Presenter: Michael Pinkawa, M.D., Ph.D.
  • Poster Presentation (No : 2869): Biodegradable Hydrogel Spacer Injection for Contralateral Submandibular Gland Sparing in Radiation Therapy for Head and Neck Cancers
    • Time/Location: 2:45 p.m. – 4:15 p.m. Poster Hall
    • Presenter: Avani Rao, M.D.
  • Poster Presentation (No : 2435): Novel Use of a Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum for Radiation Therapy for Pancreatic Cancer
    • Time/Location: 4:45 p.m. – 6:15 p.m. Poster Hall
    • Presenter: Avani Rao, M.D.

Read "Augmenix Announces Positive Three-Year Long-Term Data for SpaceOAR Hydrogel Spacer"

For more information: www.augmenix.com

Related Content

Cleveland Clinic Researchers Reveal Biomarker for Guiding Prostate Cancer Treatment
News | Prostate Cancer | October 17, 2017
October 17, 2017 — Back-to-back discoveries from Cleveland Clinic demonstrate for the first time how a testosterone-r
IBA Announces First Use of Gating With Active Scanning Proton Therapy in Italy
News | Proton Therapy | October 17, 2017
October 17, 2017 — The Trento Azienda Provinciale per i Servizi Sanitari (APSS) and IBA announced the successful comp
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
CyberKnife System Provides Excellent Long-Term Control of Low-Risk Prostate Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | October 10, 2017
Accuray Inc. announced that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent...
News | Image Guided Radiation Therapy (IGRT) | October 10, 2017
Elekta announced that members of the Elekta MR-linac Consortium reported data related to the advancement of the company...
Stanford Trial Demonstrates Accuracy of Accuro Image-Guided Epidural System
News | Ultrasound Imaging | October 09, 2017
October 9, 2017 — A clinical trial conducted at Stanford University Medical Center...
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
Benjamin Movsas, M.D., chair of the American Society for Radiation Oncology (ASTRO) Scientific Committee, explains ho
Sponsored Content | Videos | Radiation Therapy | October 09, 2017
David Beyer, M.D., chairman of the board for the American Society of Radiation Oncology (ASTRO), discusses the key th
Overlay Init